Zealand Pharma Clinical Trials: 41 Led Studies

Archive historyOct 2022 to May 2026

68 recorded changes across Zealand Pharma trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 18 of these trials. One is shown below.

Completion date movePrimary completion confirmed actual at 2026-03-31NCT07338214 · recorded 1 May 2026

Track to read them

+64 more recorded changes · Track a drug to see every change the night it lands

Start tracking drugs

Most active programmes

The drugs appearing most often across Zealand Pharma's recently active trials. Comparator arms are excluded.

Dasiglucagon7 trials
Glepaglutide6 trials
dasiglucagon5 trials
Petrelintide5 trials
GlucaGen3 trials
ZP42073 trials

Upcoming readouts

Next primary completion dates among Zealand Pharma's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Oct 2028EASE SBS 5: Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSPhase 3

Top therapeutic areas

Conditions studied most often across Zealand Pharma's recently active trials.

Hypoglycemia11 trials
Short Bowel Syndrome6 trials
Diabetes Mellitus, Type 15 trials
Congenital Hyperinsulinism3 trials
Overweight3 trials
Obesity2 trials

Zealand Pharma trials

The 41 most significant of Zealand Pharma's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842Petrelintide	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	221 est.	13 Aug 2026
A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy ParticipantsNCT06682975ZP9830	Phase 1	Locked · track to reveal	OngoingRecruiting	124 est.	Aug 2026
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionNCT07682818Petrelintide	Phase 1	Not yet scored	OngoingRecruiting	36 est.	12 Apr 2027
EASE SBS 6Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromeNCT07228403Glepaglutide 10 mg	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	35 est.	18 Sept 2028
EASE SBS 5Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSNCT07197944Glepaglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	90 est.	23 Oct 2028
EASE SBS 3Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension TrialNCT04881825Glepaglutide	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	129 est.	Apr 2026
EASE SBS 2Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSNCT03905707glepaglutide	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	145 est.	Apr 2026
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsNCT07338214Petrelintide	Phase 1	Locked · track to reveal	Completed	48 est.	31 Mar 2026
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal FunctionNCT07076030Petrelintide	Phase 1	Locked · track to reveal	Completed	39 est.	25 Nov 2025
ZUPREMEOnce-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesNCT06662539Petrelintide	Phase 2	Locked · track to reveal	Completed	493 est.	30 Sept 2025
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of DapiglutideNCT06758583Dapiglutide 7.5 mg	Phase 1	Locked · track to reveal	Completed	30 est.	12 Apr 2025
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570NCT06000891ZP7570	Phase 1	Locked · track to reveal	StoppedTerminated	84 est.	11 Feb 2025
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismNCT03941236dasiglucagon	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	42 est.	28 Jan 2025
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1DNCT05378672Dasiglucagon	Phase 3	Locked · track to reveal	Completed	8 est.	29 Oct 2024
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy ParticipantsNCT05613387ZP8396	Phase 1	Locked · track to reveal	Completed	68 est.	13 Jun 2024
Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated AdultsNCT04824872Dasiglucagon	Phase 2	Locked · track to reveal	StoppedWithdrawn	0 est.	Feb 2023
EASE SBS 4The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel SyndromeNCT04991311Glepaglutide	Phase 3	Locked · track to reveal	Completed	12 est.	2 Feb 2023
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial ParticipantsNCT05096598ZP8396	Phase 1	Locked · track to reveal	Completed	64 est.	12 Jan 2023
EASE SBS 1Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)NCT03690206glepaglutide	Phase 3	Locked · track to reveal	Completed	106 est.	26 Jul 2022
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismNCT04172441dasiglucagon	Phase 2	Locked · track to reveal	Completed	12 est.	17 Feb 2022
A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570NCT04612517ZP7570	Early Phase 1	Locked · track to reveal	Completed	40 est.	30 Aug 2021
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.NCT04318743Glepaglutide	Phase 1	Locked · track to reveal	Completed	85 est.	10 Jun 2021
A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570NCT03994549Dual GLP-1/GLP-2 Receptor agonists	Early Phase 1	Locked · track to reveal	Completed	64 est.	2 Nov 2020
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismNCT03777176Dasiglucagon	Phase 3	Locked · track to reveal	Completed	32 est.	31 Aug 2020
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal FunctionNCT04178447Glepaglutide	Phase 1	Locked · track to reveal	Completed	16 est.	14 Jul 2020
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DMNCT03895697dasiglucagon	Phase 3	Locked · track to reveal	Completed	92 est.	30 Jul 2019
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenNCT03667053dasiglucagon	Phase 3	Locked · track to reveal	Completed	42 est.	28 Jun 2019
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV AdministrationNCT03735225Dasiglucagon	Phase 1	Locked · track to reveal	Completed	60 est.	24 Jun 2019
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DMNCT03688711Dasiglucagon	Phase 3	Locked · track to reveal	Completed	45 est.	11 Mar 2019
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsNCT03378635Dasiglucagon	Phase 3	Locked · track to reveal	Completed	170 est.	27 Apr 2018
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes MellitusNCT03216226dasiglucagon	Phase 3	Locked · track to reveal	Completed	112 est.	13 Feb 2018
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy SubjectsNCT03279302Glepaglutide	Phase 1	Locked · track to reveal	Completed	75 est.	18 Dec 2017
dasiglucagonFeasibility Trial Testing the Bionic Pancreas With ZP4207NCT02971228Insulin Lispro	Phase 2	Locked · track to reveal	Completed	13 est.	24 May 2017
glepaglutideA Phase 2 Trial Testing ZP1848 in Patients With SBSNCT02690025ZP1848	Phase 2	Locked · track to reveal	Completed	18 est.	May 2017
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed GlucagonNCT02916251ZP4207(dasiglucagon) glucagon analogue	Phase 2	Locked · track to reveal	Completed	38 est.	5 Apr 2017
Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed GlucagonNCT02660008ZP4207	Phase 2	Locked · track to reveal	Completed	81 est.	Jun 2016
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial InfarctionNCT01977755danegaptide	Phase 2	Locked · track to reveal	Completed	591 est.	20 Dec 2015
Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207NCT02390141ZP4207	Phase 1	Locked · track to reveal	Completed	24 est.	Jul 2015
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a ComparatorNCT02367053ZP4207	Phase 1	Locked · track to reveal	Completed	111 est.	Apr 2015
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending DoseNCT00868660ZP1848	Phase 1	Locked · track to reveal	Completed	66 est.	Feb 2010
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart FailureNCT00283361ZP120	Phase 2	Locked · track to reveal	StoppedTerminated	130 est.	—

View all trials41

A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants

Phase 1RecruitingNCT06682975 ↗

Primary completion: Aug 2026; estimated
Enrollment: 124; estimated
Start: Nov 2024; Zealand Pharma

Conditions

Healthy Volunteers

Interventions

ZP9830
Placebo

Brief summary

The primary object in this research study is to investigate the safety and tolerability of ZP9830 in healthy study participants, and in addition, the study will investigate how ZP9830 works in the body (pharmacokinetics, PK and pharmacodynamics, PD) compared to placebo.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Completion date move · 1

Enrollment change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

EASE SBS 6: Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Phase 3Enrolling by invitationNCT07228403 ↗

Primary completion: Sept 2028; estimated
Enrollment: 35; estimated
Start: Dec 2025; Zealand Pharma

Conditions

Short Bowel Syndrome (SBS)

Interventions

Glepaglutide 10 mg

Brief summary

The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials. Participants currently on these trials will be able to continue their glepaglutide treatment by…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

EASE SBS 3: Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Phase 3Active, not recruitingNCT04881825 ↗

Primary completion: Apr 2026; estimated
Enrollment: 129; estimated
Start: Jun 2021; Zealand Pharma

Conditions

Short Bowel Syndrome

Interventions

Glepaglutide

Brief summary

This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Mar 2026

Status change · 2

Completion date move · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

Phase 1CompletedNCT07338214 ↗

Primary completion: Mar 2026; actual
Enrollment: 48; estimated
Start: Dec 2025; Zealand Pharma

Conditions

Obesity & Overweight

Interventions

Petrelintide

Brief summary

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases. The goal is to learn how the same single dose of petrelintide, given using different concentrations, works in the body…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

Phase 1CompletedNCT07076030 ↗

Primary completion: Nov 2025; actual
Enrollment: 39; estimated
Start: Apr 2025; Zealand Pharma

Conditions

Renal Impairment

Interventions

Petrelintide

Brief summary

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with comorbidities or related diseases. The aim of this clinical research study is to investigate whether the effects of petrelintide will be different in…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Feb 2026

Completion date move · 1

Enrollment change · 1

Status change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Phase 1CompletedNCT06758583 ↗

Primary completion: Apr 2025; actual
Enrollment: 30; estimated
Start: Dec 2024; Zealand Pharma

Conditions

Overweight and Obesity

Interventions

Dapiglutide 7.5 mg

Brief summary

This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL. The trial will be conducted…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jul 2025

Status change · 1

Completion date move · 1

Enrollment change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Phase 1TerminatedNCT06000891 ↗

Primary completion: Feb 2025; actual
Enrollment: 84; estimated
Start: Sept 2023; Zealand Pharma

Conditions

Safety and Tolerability

Interventions

ZP7570
Placebo

Brief summary

The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2 in overweight and obese but otherwise healthy subjects, randomised to ZP7570 or placebo…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Apr 2025

Completion date move · 3

Status change · 2

Enrollment change · 2

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Phase 3Active, not recruitingNCT03941236 ↗

Primary completion: Jan 2025; actual
Enrollment: 42; estimated
Start: May 2019; Zealand Pharma

Conditions

Congenital Hyperinsulinism

Interventions

dasiglucagon

Brief summary

This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176) (defined as lead-in trials). The primary objective is to evaluate the long-term safety of…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Feb 2026

Completion date move · 3

Enrollment change · 1

Status change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Phase 3CompletedNCT05378672 ↗

Primary completion: Oct 2024; actual
Enrollment: 8; estimated
Start: May 2023; Zealand Pharma

Conditions

Hypoglycemia
Type 1 Diabetes

Interventions

Dasiglucagon

Brief summary

This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use. In addition, the study will investigate how dasiglucagon works in the body (pharmacokinetics and pharmacodynamics). Participants will receive 1 single dose as an injection…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Aug 2025

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Phase 1CompletedNCT05613387 ↗

Primary completion: Jun 2024; actual
Enrollment: 68; estimated
Start: Nov 2022; Zealand Pharma

Conditions

Overweight
Healthy Volunteers
Obese

Interventions

ZP8396
Drug: Placebo (ZP8396)

Brief summary

The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial in normal weight and overweight but otherwise healthy subjects randomised to subcutaneous administration of ZP8396 or placebo

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jul 2024

Completion date move · 3

Enrollment change · 2

Status change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Phase 2WithdrawnNCT04824872 ↗

Primary completion: Feb 2023; estimated
Enrollment: 0; estimated
Start: Feb 2023; Zealand Pharma

Conditions

Hypoglycemia
Glucose Metabolism Disorders

Interventions

Dasiglucagon
Dasiglucagon
Placebo

Brief summary

The objective of the trial is to assess the effect of single subcutaneous doses of dasiglucagon versus placebo on post-prandial plasma glucose nadir following a Mixed Meal Test in Roux-en-Y Gastric Bypass (RYGB) subjects

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Apr 2023

Enrollment change · 1

Completion date move · 1

Status change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

EASE SBS 4: The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

Phase 3CompletedNCT04991311 ↗

Primary completion: Feb 2023; actual
Enrollment: 12; estimated
Start: Aug 2021; Zealand Pharma

Conditions

Short Bowel Syndrome

Interventions

Glepaglutide

Brief summary

The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS). The trial will also investigate whether glepaglutide is safe during long-term use. All participants in the trial will receive glepaglutide…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Oct 2023

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

Phase 1CompletedNCT05096598 ↗

Primary completion: Jan 2023; actual
Enrollment: 64; estimated
Start: Oct 2021; Zealand Pharma

Conditions

Overweight
Healthy Volunteers

Interventions

ZP8396
Placebo (ZP8396)

Brief summary

The research study will investigate the safety and tolerability of ZP8396 in healthy study participants. In addition, the study will investigate how ZP8396 works in the body (pharmacokinetics and pharmacodynamics). Participants will receive 1 single dose either as an injection under the skin (subcutaneous, s.c.) or…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2023

Completion date move · 2

Status change · 2

Enrollment change · 1

Track Zealand Pharma drugs to see every change the night it lands.

Start tracking drugs